LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Search

Ionis Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

71.42 2.25

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

70.74

Max

71.5

Galvenie mērījumi

By Trading Economics

Ienākumi

-252M

-129M

Pārdošana

-295M

157M

EPS

-0.613

Peļņas marža

-82.062

Darbinieki

1,069

EBITDA

-263M

-112M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+21.46% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-370M

11B

Iepriekšējā atvēršanas cena

69.17

Iepriekšējā slēgšanas cena

71.42

Ziņu noskaņojums

By Acuity

50%

50%

185 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Neutral Evidence

Ionis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 14. nov. 17:45 UTC

Peļņas
Galvenie tirgus virzītāji

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

2025. g. 14. nov. 17:31 UTC

Peļņas
Galvenie tirgus virzītāji

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

2025. g. 14. nov. 16:15 UTC

Galvenie tirgus virzītāji

Scholar Rock Shares Rise on Renewed Apitegromab Hopes

2025. g. 14. nov. 23:56 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

2025. g. 14. nov. 23:02 UTC

Tirgus saruna

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

2025. g. 14. nov. 22:35 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

2025. g. 14. nov. 22:32 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

2025. g. 14. nov. 22:29 UTC

Peļņas

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

2025. g. 14. nov. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

2025. g. 14. nov. 21:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 14. nov. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

2025. g. 14. nov. 20:27 UTC

Tirgus saruna

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

2025. g. 14. nov. 20:23 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

2025. g. 14. nov. 20:17 UTC

Iegādes, apvienošanās, pārņemšana

Several State Attorneys General Oppose Railroad Merger -- WSJ

2025. g. 14. nov. 19:29 UTC

Tirgus saruna
Peļņas

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

2025. g. 14. nov. 18:44 UTC

Tirgus saruna
Peļņas

Disney's Growth Now Hinges More on ESPN -- Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 14. nov. 18:27 UTC

Tirgus saruna

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

2025. g. 14. nov. 18:20 UTC

Tirgus saruna

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2025. g. 14. nov. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2025. g. 14. nov. 17:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 14. nov. 16:51 UTC

Tirgus saruna

Starbucks Gets Holiday Sales Lift -- Market Talk

2025. g. 14. nov. 16:48 UTC

Tirgus saruna

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

2025. g. 14. nov. 16:38 UTC

Tirgus saruna

Unica Reports Higher Brazilian Sugar and Ethanol Production -- Market Talk

2025. g. 14. nov. 16:30 UTC

Iegādes, apvienošanās, pārņemšana

Merck Is Paying Up for Flu Biotech as M&A Spree Continues -- Barrons.com

2025. g. 14. nov. 16:28 UTC

Tirgus saruna

Ukraine Strike on Russian Port Lifts Distillates -- Market Talk

2025. g. 14. nov. 15:59 UTC

Tirgus saruna

U.S. Natural Gas Inventories Rise More Than Expected -- Market Talk

2025. g. 14. nov. 15:06 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 14. nov. 15:06 UTC

Tirgus saruna

Dollar Could Benefit From U.K., French Fiscal Concerns -- Market Talk

Salīdzinājums

Cenas izmaiņa

Ionis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

21.46% augšup

Prognoze 12 mēnešiem

Vidējais 84.83 USD  21.46%

Augstākais 110 USD

Zemākais 65 USD

Pamatojoties uz 20 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Ionis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

20 ratings

17

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

29.78 / 33.645Atbalsts un pretestība

Īstermiņā

Neutral Evidence

Vidējā termiņā

Very Strong Bullish Evidence

Ilgtermiņā

Bearish Evidence

Noskaņojums

By Acuity

185 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat